influenza-resistant drugs and vaccines demand increase
Custom Synthesis, Since December 2017, there has been a seasonal peak in influenza, the percentage of influenza-like cases and the positive rate of influenza virus detection are significantly higher than in previous three years, the number of severe cases has increased markedly, and in some areas there has been a temporary shortage of influenza drugs.
In general, the flu season related to the prevention and treatment of drug market demand has increased significantly, pulling related over-the-counter drug sales. In 2017, global consumer over-the-counter spending was $29 billion trillion, which is expected to continue to grow in the next five years, according to Iqvia, an American market research firm.
Among them, colds and flu drugs (including cough/cold medicine, throat medicine and nasal subtraction) accounted for 22.5% of the global over-the-counter drug market share. Oseltamivir is currently recognized as the most effective antiviral drug in the influenza-resistant drug market. China Pharmaceutical Industry Information Center Drug Synthesis Database (PDB) data show that 2017 years ago 3 quarters, the anti-influenza drug market (oseltamivir, Peramivir, Amantadine, Zanamivir), Austrian Secretary of the sales amount of up to 92.53%
The World Health Organization says the most effective way to prevent influenza is to vaccinate. After vaccination, the immune system gradually weakened over time, so it is recommended that influenza vaccines be vaccinated before the onset of the annual influenza season.
Currently, the world’s most commonly used influenza vaccine is inactivated influenza vaccine. The industry believes that the threat of future influenza will also exist for a long time, the development of effective anti-influenza drugs has become the world’s common expectations. Structural modification of existing drugs, discovery of new drug targets and the search for new natural drugs will be the main direction of development in the future. For domestic pharmaceutical companies, to prepare for the production of influenza-resistant varieties and product supply chain, to meet the market’s temporary “soaring” demand.http://www.haihengpharma.com/influenza-resistant-drugs-and-vaccines-demand-increase/News